Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00110864 · ClinicalTrials.gov registry record · Phase 2

Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

A Phase 2 study, sponsored by Wellstat Therapeutics.

Completed
Registry status
Phase 2
Development phase
90
Enrollment target

NCT00110864: Completed Phase 2 study, sponsored by Wellstat Therapeutics.

NCT00110864 is a Phase 2 study that has completed, run by Wellstat Therapeutics. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00110864, a Phase 2 study, has completed, sponsored by Wellstat Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
90 participants
Enrollment target

Study Summary

This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will also be measured.

Interventions

  • DRUG Insulin
  • DRUG PN2034

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2005-05
Est. Completion 2007-04
Phase Phase 2
Wellstat Therapeutics

5 total trials

What the finished NCT00110864 record still lists

NCT00110864 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).

The record links to 0 conditions, and to 2 interventions - of which Insulin is the first listed.

NCT00110864 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00110864 about?

NCT00110864 is a clinical study titled "Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes". This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will also be measured.

What is the current status of trial NCT00110864?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2005-05. Estimated completion is 2007-04.

What interventions are being tested in trial NCT00110864?

The interventions under investigation include: Insulin (DRUG), PN2034 (DRUG).

Who is sponsoring clinical trial NCT00110864?

This trial is sponsored by Wellstat Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00110864's enrollment target sits among peer trials

90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00110864, the US trial registry maintained by the National Library of Medicine. NCT00110864 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.